IDEXX Laboratories Inc. and Applied BioCode announced that they have entered into an exclusive global agreement to bring Applied BioCode’s digital multiplex platform to IDEXX Reference Laboratory customers. IDEXX anticipates the technology will be commercially available starting in 2019. Paired with IDEXX’s proprietary assays and reagents, Applied BioCode’s technology enables the development of an ultra-high sensitivity immunoassay platform. Immunoassay is the detection technology used on platforms such as SNAP for applications as diverse as vector-borne disease and parasitology, and for both sick and preventive care uses.